A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With R... by Kathryn E. Beckermann, MD, PhD, Christine M. Bestvina, MD, Badi El Osta, MD, Rachel E. Sanborn, MD, Hossein Borghaei, MD, Philip Edward Lammers, MD, MSCI, Giovanni Selvaggi, MD, Jennifer G. Whisenant, PhD, Ellen Heimann-Nichols, MBA, Lynne Berry, PhD, Chih-Yuan Hsu, PhD, Yu Shyr, PhD, Leora Horn, MD, MSc, MHPE, Heather Wakelee, MD, FASCO

Get full text